[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0929575A4 - Novel human growth factors - Google Patents

Novel human growth factors

Info

Publication number
EP0929575A4
EP0929575A4 EP97924803A EP97924803A EP0929575A4 EP 0929575 A4 EP0929575 A4 EP 0929575A4 EP 97924803 A EP97924803 A EP 97924803A EP 97924803 A EP97924803 A EP 97924803A EP 0929575 A4 EP0929575 A4 EP 0929575A4
Authority
EP
European Patent Office
Prior art keywords
growth factors
human growth
novel human
novel
factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97924803A
Other languages
German (de)
French (fr)
Other versions
EP0929575A1 (en
Inventor
Guo-Liang Yu
Patrick J Dillon
Reinhard Ebner
Gregory A Endress
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP0929575A1 publication Critical patent/EP0929575A1/en
Publication of EP0929575A4 publication Critical patent/EP0929575A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP97924803A 1996-08-23 1997-08-22 Novel human growth factors Withdrawn EP0929575A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/US96/13766 1996-08-23
US9613766 1996-08-23
PCT/US1997/014139 WO1998007749A1 (en) 1996-08-23 1997-08-22 Novel human growth factors

Publications (2)

Publication Number Publication Date
EP0929575A1 EP0929575A1 (en) 1999-07-21
EP0929575A4 true EP0929575A4 (en) 2004-09-08

Family

ID=22255670

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97924803A Withdrawn EP0929575A4 (en) 1996-08-23 1997-08-22 Novel human growth factors

Country Status (4)

Country Link
EP (1) EP0929575A4 (en)
JP (1) JP2002508652A (en)
AU (1) AU3011497A (en)
WO (1) WO1998007749A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002559A1 (en) * 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
AU2005218046B2 (en) * 2000-02-25 2008-07-03 Ucb Pharma S.A. Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
AU2001233913A1 (en) * 2000-02-25 2001-09-03 Oxford Glycosciences (Uk) Ltd. Bcmp 84, a protein associated to breast cancer
US20040141974A1 (en) * 2000-02-25 2004-07-22 Boyd Robert Simon Diagnostic and therapeutic methods
AU2001259160A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
EP1702928A3 (en) * 2000-06-02 2006-09-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
RU2166957C1 (en) * 2000-10-09 2001-05-20 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Tetrapeptide stimulating functional activity of hepatocytes, pharmacological agent based on thereof and method of its use
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
JP2004298112A (en) * 2003-03-31 2004-10-28 Japan Science & Technology Agency Human solid cancer antigen peptide, polynucleotide encoding the same and utilization thereof
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
ES2299281B1 (en) * 2003-10-22 2009-04-16 Progenika Biopharma, S.A. METHODS FOR IN VITRO AND FORECAST IN VITRO DIAGNOSIS OF THE CANCER OF PANCREAS, AND FOR THE DEVELOPMENT OF PHARMACOS AGAINST CANCER OF PANCREAS.
JP2007520217A (en) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． Novel nucleotide and amino acid sequences, and assays and methods of use for breast cancer diagnosis using the same
WO2008026009A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Protein
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN104023718B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
CN104023727B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of children's cholestatic liver disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
KR20230152818A (en) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JP7562546B2 (en) 2019-02-12 2024-10-07 ミルム ファーマシューティカルズ インコーポレイテッド Methods for increasing growth in pediatric subjects with cholestatic liver disease - Patents.com

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
WO1998041627A1 (en) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted polypeptides with homology to xenopus cement gland proteins
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
WO1998041627A1 (en) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted polypeptides with homology to xenopus cement gland proteins
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL, HEIDELBERG, FRG [online] 1 January 1998 (1998-01-01), SIVE, H. ET AL.: "Cement gland-specific", XP002275165, Database accession no. O42251 *
DATABASE EMBL, HEIDELBERG, FRG [online] 17 June 1999 (1999-06-17), "Human 5' EST secreted protein SEQ ID NO: 343", XP002275164, Database accession no. AAY12312 *
DATABASE EMBL, HEIDELBERG, FRG [online] 17 June 1999 (1999-06-17), "Human secreted protein 5' EST SEQ ID NO: 89", XP002275183, Database accession no. AAX41145 *
DATABASE EMBL, HEIDELBERG, FRG [online] 5 December 1996 (1996-12-05), SIVE, H. ET AL.: "Xenopus laevis putative secreted protein XAG (XAG) mRNA, complete cds", XP002275163, Database accession no. U76752 *
DATABASE EMBL, HEIDELBERG,FRG [online] 9 September 1994 (1994-09-09), FRIGERIO, J.M. ET AL.: "EST050 Human colorectal cancer Homo sapiens cDNA clone 2B10, mRNA sequence", XP002275162, Database accession no. T24475 *
See also references of WO9807749A1 *
SIVE, H. & BRADLEY, L.: "A Sticky Problem: The Xenopus Cement Gland as a Paradigm for Anteroposterior Patterning", DEVELOPMENTAL DYNAMICS, vol. 205, no. 3, March 1996 (1996-03-01), pages 265 - 280, XP002072379 *
THOMPSON, D.A. & WEIGEL, R.J.: "hAG-2, the Human Homologue of the Xenopus laevis Cement Gland Gene XAG-2, Is Coexpressed with Estrogen Receptor in Breast Cancer Cell Lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 251, no. 1, 9 October 1998 (1998-10-09), pages 111 - 116, XP001009725 *

Also Published As

Publication number Publication date
JP2002508652A (en) 2002-03-19
EP0929575A1 (en) 1999-07-21
WO1998007749A1 (en) 1998-02-26
AU3011497A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
EP0871705A4 (en) Human ccn-like growth factor
PL328822A1 (en) Human bikinine
EP0741578A4 (en) Human growth hormone
EP0929575A4 (en) Novel human growth factors
EP0904292A4 (en) Growth differentiation factor-14
AU130614S (en) Tissue
GB9619492D0 (en) Novel treatment
GB9615767D0 (en) Novel treatment
GB9608657D0 (en) Novel treatment
EP0879240A4 (en) Human criptin growth factor
AU5487598A (en) Breast implant
EP0891372A4 (en) Growth factor htter36
GB9424232D0 (en) Growth factor expression
GB9625795D0 (en) Novel treatment
GB9617550D0 (en) Medical ice-pack
GB9619489D0 (en) Growth factors
GB2319479B (en) Surgical implant
GB9612752D0 (en) Novel treatment
GB9719794D0 (en) Growth Factors
IL119451A (en) Artificial hand
GB9403496D0 (en) Mushroom growth unit
GB9606668D0 (en) Tissue prosthesis
GB9620416D0 (en) Prosthesis
GB9604661D0 (en) Prosthesis
GB9604915D0 (en) Prosthesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61K 38/18 B

Ipc: 7G 01N 33/53 B

Ipc: 7G 01N 33/50 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 07K 16/18 B

Ipc: 7C 07K 14/475 B

Ipc: 7C 12N 15/12 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040721

17Q First examination report despatched

Effective date: 20060828

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070301